Abstract
Background: Bladder cancer is a common urological cancer associated high significant morbidity and mortality rates. Immunotherapy has emerged as a promising treatment option, although response rates vary among patients. Glycosylation has been implicated in tumorigenesis and immune regulation. However, our current comprehensive understanding of the role of glycosylation in bladder cancer and its clinical implications is limited.
Methods: We constructed a training cohort based on the downloaded TCGA-BLCA dataset, while additional datasets (Xiangya cohort, GSE32894, GSE48075, GSE31684, GSE69795 and E-MTAB-1803) from Xiangya hospital, GEO and ArrayExpress database were obtained and used as validation cohorts. To identify glycosylation-related genes associated with prognosis, univariate Cox regression and LASSO regression were performed. A Cox proportional hazards regression model was then constructed to develop a risk score model. The performance of the risk score was assessed in the training cohort using Kaplan-Meier survival curves and ROC curves, and further validated in multiple validation cohorts.
Results: We classified patients in the training cohort into two groups based on glycosylation-related gene expression patterns: Cluster 1 and Cluster 2. Prognostic analysis revealed that Cluster 2 had poorer survival outcomes. Cluster 2 also showed higher levels of immune cell presence in the tumor microenvironment and increased activation in key steps of the cancer immune response cycle. We developed an independent prognostic risk score (p < 0.001) and used it to construct an accurate prognostic prediction nomogram. The high glycosylation risk score group exhibited higher tumor immune cell infiltration, enrichment scores in immune therapy-related pathways, and a tendency towards a basal subtype. Conversely, the low-risk score group had minimal immune cell infiltration and tended to have a luminal subtype. These findings were consistent in our real-world Xiangya cohort.
Conclusion: This multi-omics glycosylation score based on these genes reliably confirmed the heterogeneity of bladder cancer tumors, predicted the efficacy of immunotherapy and molecular subtypes, optimizing individual treatment decisions.
Introduction
Bladder cancer (BLCA) is a prevalent malignancy worldwide, characterized by high morbidity and mortality rates (Siegel et al., 2020). Non-muscle invasive bladder cancer (NMIBC) accounts for three-quarters of initial diagnoses, while the remaining cases are categorized as either muscle-invasive bladder cancer (MIBC) or BLCA with distant metastasis (Powles et al., 2022). Despite advancements in treatment options, such as surgery and chemotherapy, the prognosis for patients with advanced stage BLCA remains suboptimal (Antoni et al., 2017; Lenis et al., 2020). Recent studies have shown that monoclonal antibodies targeting PD-1 and its ligands have emerged as a therapeutic strategy with encouraging clinical benefits for metastatic BLCA (Rosenberg et al., 2016; Plimack et al., 2017; Rijnders et al., 2017; Hu et al., 2022). However, only a subset of patients can achieve beneficial (Jenkins et al., 2018; Schoenfeld and Hellmann, 2020). Although increased expression of PD-L1 on tumor cells and/or immune cells is currently used as a diagnostic method for immune therapies targeting PD-1, it only partially correlates with the clinical benefits of these drugs (Ma et al., 2016). Therefore, there is an urgent requirement to discover novel biomarkers that can assist in treatment decision-making and improve patient outcomes.
The tumor immune microenvironment (TIME) is an intricate milieu consisting of immune cells and immune-related molecules (Binnewies et al., 2018), and its importance in immunotherapy has gained widespread recognition. Chen DS et al. categorized TIME into three subtypes: “immune inflamed,” “immune excluded,” and “immune desert,” based on their distinct characteristics and potential responsiveness to immunotherapy (Chen and Mellman, 2017). Similarly, Duan Q et al. classified tumors as either “hot” or “cold” tumors depending on the level of immune infiltration (Duan et al., 2020). Cold and immune desert tumors are characterized by limited immune cell infiltration, resulting in a poor response to immunotherapy (Galon and Bruni, 2019). Emerging therapeutic strategies are focused on enhancing immune infiltration to transform the tumor microenvironment (TME), from a poorly infiltrated “cold” phenotype to an immune-rich “hot” phenotype (Bonaventura et al., 2019; Vonderheide, 2020). Therefore, analyzing the TIME is crucial for enhancing the efficacy of immunotherapy.
Glycosylation, a common post-translational protein modification process, occurs in all domains of life (Pinho and Reis, 2015). It involves the attachment of monosaccharides or polysaccharides (i.e., oligosaccharides or complex glycans) to specific residues of target proteins (Eichler, 2019). This modification has been reported to impact various biological processes, including protein secretion, degradation, transport to receptor interactions, and modulation of immune responses (Moremen et al., 2012; Varki, 2017). Glycosylation is associated with the pathogenesis of numerous prevalent diseases, including cancer (Eichler, 2019). Glycosylation modification affects tumorigenesis through its influence on growth, differentiation, metastasis, and immune surveillance. Altered glycosylation profiles have been detected in various types of cancer, including BLCA (Przybylo et al., 2002; RodrÍguez et al., 2018). For instance, the invasive capacity of BLCA cells has been linked to the N-glycosylation of cadherin (Przybylo et al., 2002). Furthermore, glycosylation has been implicated in the regulation of immune responses within the TIME (Badmann et al., 2020; Sun et al., 2021). However, our understanding of the glycosylation landscape in BLCA and its clinical implications is still limited. Given the critical role of glycosylation in both tumorigenesis and immune regulation, it is plausible that glycosylation patterns could serve as potential biomarkers for predicting the response to immunotherapy in BLCA patients.
In this study, our research objective is to develop a new glycosylation risk score based on a multi-omics study to evaluate the prognosis comprehensively and individually, immunophenotype, and tumor heterogeneity of BLCA patients. In addition, we aim to study the glycosylation risk score to provide valuable insights into the potential of BLCA patients to make treatment decisions such as personalized immunotherapy and improve their prognosis.
Materials and methods
Data collection
Training set
We established a dataset consisting of 408 patients with BLCA by selecting individuals from the Cancer Genome Atlas (TCGA) database. The mRNA expression matrix and clinical information corresponding to these patients were downloaded from the Genomic Data Commons (GDC, https://portal.gdc.cancer.gov/) (Colaprico et al., 2016). We converted the fragments per kilobase of exon model per million mapped fragments (FPKM) and count value in the original expression matrix to transcripts per kilobase of exon model per million mapped reads (TPM). Subsequently, we merged this data with clinical information to create a new dataset. After excluding 5 patients due to duplicated or missing follow-up data, a total of 403 patients formed the training cohort.
Validation cohorts
In our early-stage study (Li et al., 2021), we constructed a dataset called the Xiangya cohort and have uploaded it to the Gene Expression Omnibus (GEO) database. This dataset includes 56 patients with BLCA and encompasses complete survival information along with RNA-sequencing (RNA-seq) data (GSE188715). We also downloaded relevant data from the GEO database (https://www.ncbi.nlm.nih.gov/geo/) to construct four additional external validation cohorts (GSE32894, GSE48075, GSE31684 and GSE69795). Duplicate patients or those with incomplete survival information were excluded during data preprocessing, resulting in a final inclusion of 224 (GSE32894), 73 (GSE48075), 93 (GSE31684) and 38 (GSE69795) individuals in the four cohorts, respectively. Download the dataset with accession number E-MTAB-1803 from the ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) as an additional external validation cohort.
Supplementary Table S1 displays the clinical information of patients in the training and six validation cohorts.
Consensus clustering
We obtained a list of 628 glycosylation-related genes from the gene set enrichment analysis (GSEA) (Supplementary Table S2). To analyze the expression pattern of these genes in training cohort, we utilized the consensus clustering function in the “ConsuClusterPlus” R package (Wilkerson and Hayes, 2010). The parameters were set as follows: distance = “manhattan”, clusterAlg = “pam”, maxK = 5, Reps = 1,500, pItem = 0.8, pFeature = 1. By applying this approach, we identified distinct glycosylation expression patterns.
Describing the TIME of BLCA
To characterize the TIME of BLCA, we utilized the tracking tumor immunophenotype (TIP) database (http://biocc.hrbmu.edu.cn/TIP/) (Xu et al., 2018) to obtained the activation levels of the 7-step Cancer Immunity Cycle (CIC) (Chen and Mellman, 2013). Furthermore, we compiled a summary of 22 immune checkpoint inhibitor (ICI) genes, 18 T cell-associated inflammatory signature (TIS) genes, and effector genes of various immune cells, including CD8 T cells, dendritic cells (DCs), macrophages, natural killer (NK) cells, and type 1 T helper (Th1) cells, based on our previous study (Hu et al., 2021a) (Supplementary Table S3).
Development of glycosylation risk score
To identify candidate genes associated with glycosylation patterns and clinical prognosis, we employed two methods: Univariate Cox analysis and the least absolute shrinkage and selection operator (LASSO) algorithm. The “glmnet” R package was utilized for the LASSO algorithm. Initially, Initially, we conducted univariate Cox analysis on a set of 628 genes and identified 30 genes that were strongly correlated with prognosis (p < 0.005). Subsequently, the LASSO algorithm was applied to further refine the prognostic genes. The “glmnet” R package facilitated this process. From the LASSO analysis, we identified 20 candidate genes. Finally, the glycosylation risk score was constructed using the Cox proportional hazard regression model with the “glmnet” R package, incorporating 20 genes.
Evaluation and verification of glycosylation risk score
In the training set, patients were divided into high-risk and low-risk groups based on their risk scores, using the median of the risk score as the threshold. Kaplan-Meier (K-M) survival curves were plotted and the log-rank test was performed using the “survminer” R package to assess the differences in survival between the two groups. The predictive accuracy of the risk score was evaluated using the time-dependent receiver operating characteristic (tROC) analysis, implemented with the “tROC” R package. Additionally, a nomogram was constructed incorporating clinical information related to prognosis and the glycosylation risk score. The predictive efficacy of the nomogram was verified using calibration curves.
For external validation, the same method used in the training set was applied to an independent cohort of BLCA patients. In brief, the risk scores were calculated using the glycosylation risk scoring formula, and patients were classified into high-risk and low-risk groups using the median risk score as the threshold. The survival outcomes between the two groups were compared using the K-M method and log-rank test. The predictive accuracy of the risk scores was evaluated using tROC analysis.
Identification of molecular subtypes of BLCA by glycosylation risk score
In our previous studies, our team conducted an extensive review and summary of the existing seven molecular typing criteria for BLCA, including the TCGA, UNC, and Consensus systems, et al. To achieve a unified classification approach, we utilized two R packages, namely, “BLCAsubtyping” and “ConsensusMIBC”. Additionally, we incorporated BLCA-related pathways identified by Kamoun, A. et al. (Kamoun et al., 2020) (Supplementary Table S4). To enhance clinical applicability, we further reclassified the different molecular subtypes into “luminal” and “basal” subtypes, aiming to provide a more concise and efficient clinical guidance.
Statistical analysis
Correlations between variables were assessed using either Pearson or Spearman coefficients, depending on the nature of the data. Differences between binary groups in continuous variables were evaluated using the t-test or Mann-Whitney U test. To examine the survival prognosis, the K-M method was employed to generate survival curves, and statistical significance was determined using the log-rank test. The relationship between candidate genes and survival prognosis was determined through univariate Cox analysis, and the LASSO algorithm was used to select and refine the candidate genes for constructing the glycosylation risk score. The hazard ratio (HR) and independent prognostic values of the glycosylation risk score were calculated using univariate and multivariate Cox regression models. The glycosylation risk score was constructed using the Cox proportional hazard regression model, and its accuracy was assessed by drawing time-dependent receiver operating characteristic (ROC) curves and calculating the area under the curve (AUC). All statistical analyses were conducted using R software (version 4.22) with a significance level set at p < 0.05. The adjusted p-value was obtained using the false discovery rate (FDR) method, and all tests were two-sided.
Results
Construction of glycosylation genes expression patterns related to prognosis and tumor immune microenvironment
We constructed expression patterns based on glycosylation genes features using unsupervised clustering analysis in the TCGA-BLCA cohort, by “ConsenseClusterPlus” R package. And we found that dividing into two patterns was the most appropriate, named glycosylation cluster 1 and glycosylation cluster 2. (Figure 1A). Subsequently, we conducted a detailed analysis to investigate the disparities between the two mentioned glycosylation clusters. In terms of prognosis, compared to cluster 1, cluster 2 has a significantly poorer prognosis (p = 0.024, Figure 1B). As for the TIME, as depicted in Figure 1C (Supplementary Table S5), the infiltration level of most of immune cells including activated and immature B cell, activated and central memory CD4 T cell, activated and central memory CD8 T cell, natural killer cell and macrophage in TME was apparently higher in cluster 2 compared to cluster 1. In addition, in the 7-step CIC, cluster 2 exhibited a higher activation level in the main anti-tumor immune steps, including step 1 (release of cancer cell antigens), step 4 (recruitment of immune cells such as T cell, CD8 T, macrophage, NK cell, dendritic cell), step 6 (recognition of cancer cells by T cells) and step 7 (killing of cancer cells) (Figure 1D; Supplementary Table S6).
FIGURE 1
Developing glycosylation-related risk scores and predicting clinical outcomes in multiple cohorts
The completely different manifestations of these two glycosylation clusters mentioned above in the prognosis and TIME of BLCA aroused our interest. Therefore, we planned to develop a quantitative risk score utilizing the expression patterns of glycosylation genes. This risk score will be used to predict the clinical prognosis of each patient, aiming to achieve the accuracy treatment of BLCA.
Firstly, we selected 30 independent prognostic genes strongly associated with prognosis from glycosylation-related genes through univariate analysis (p < 0.005, Supplementary Table S7). Subsequently, LASSO regression helped us identify the 20 most suitable candidate genes in those 30 independent prognostic genes above for constructing glycosylation-related risk models (Figures 2A, B; Supplementary Table S8). And we choose the minimum lambda for the optimal cutoff value, and selected ten-fold cross validation method as correction. Finally, based on those 20 candidate glycosylation genes above, we employed the “glmnet” R software package to construct a Cox proportional risk regression model. This model allowed us to generate a risk score, known as the glycosylation-based risk score, in the TCGA-BLCA training cohort. The median glycosylation risk score would be used as a standard to classify the patients in cohorts into high and low score groups.
FIGURE 2
To investigate the potential clinical utility of glycosylation risk score, we first included it as an independent clinical indicator through univariate COX analysis. Our findings revealed that the glycosylation risk score, along with other clinical pathological factors such as tumor grade, stage of BLCA, age, and gender, significantly influenced prognosis (p < 0.001, Figure 2C). As shown in Figure 2D, subsequent multivariate Cox analysis demonstrated that the glycosylation risk score remains an independent prognostic indicator (p < 0.001). A glycosylation specific nomogram was developed using those independent prognostic factors identified by multivariate COX analysis (glycosylation risk score, age, and tumor stage) suggested that glycosylation risk score, like other clinical information, have important predictive value for prognosis (Figure 2E). The results indicated that glycosylation score accounted for a considerable proportion of the nomogram score, so its level could largely accurately predict the survival probability of a single patient at 1, 3, and 5 years. Furthermore, it was found that patients with higher glycosylation score had poorer prognosis, and there was an urgent need for new treatment methods to improve prognosis of these patients. In addition, the calibration curve indicated that the predicted OS of the glycosylation specific nomogram was very close to the real OS (Figure 2F), and the Q-Q plot had verified the normality of the above data (Supplementary Figure S1).
To further determine the prognostic significance of glycosylation risk score in BLCA, we validated its predictive value in multiple cohorts, including both public databases and our own real-world study. In the training cohort TCGA-BLCA, we observed that patients with a high glycosylation risk score had significantly worse prognosis compared to those with a low glycosylation risk score (p < 0.0001, Figure 3A). Additionally, the glycosylation risk score exhibited high accuracy in predicting 1-year, 3-year, and 5-year survival rates, with respective values of 0.75, 0.74, and 0.75 (Figure 3B). Meanwhile, in our real-world cohort (Xiangya BLCA cohort), the prognosis of the high glycosylation score group remained significantly poor (p = 0.014, Figure 3C) and its predictive accuracy was relatively high (1, 3, and 5 years accuracy: 0.75, 0.71 and 0.56 separately, Figure 3D). The above results remain robust: the prognosis of the high glycosylation score group presented obviously worse, in other public database cohorts, including E-MTAB-1803 (p = 0.00019, 1-year, 3-year, and 5-year accuracy: 0.73, 0.76 and 0.77 separately, Figures 3E, F), GSE32894 (p < 0.0001, 1-year, 3-year, and 5-year accuracy: 0.83, 0.89 and 0.88 separately, Figures 3G, H), GSE48075 (p = 0.00012, 1-year, 3-year, and 5-year accuracy: 0.82, 0.78 and 0.76 separately, Figures 3I, J), and two other GEO BLCA cohorts (Supplementary Figure S2).
FIGURE 3
The above results fully confirmed that glycosylation risk score can reliably predict the clinical outcomes of BLCA, and its predictive value had high accuracy and internal and external authenticity, which can be widely promoted to other cohorts.
Exploring the relationship between glycosylation score and TIME in the TCGA-BLCA cohort
The accurate prediction of glycosylation score for prognosis had sparked our interest in deeper research, therefore, we continued to investigate its association with the TIME in the TCGA-BLCA cohort. As shown in the single-sample gene set enrichment analysis (ssGSEA) analysis (Figure 4A; Supplementary Table S9), we found that compared to the low glycosylation score patients, the infiltration level of major tumor immune cells significantly increased in patients with high glycosylation score, such as central memory CD8/CD4 T cell, natural killer T cell, natural killer cell, regulatory T cell and memory B cell. The correlation between representative immune cells infiltration and glycosylation score were shown in Figure 4B and Supplementary Figure S3, Meanwhile, the activation of major steps of 7-step CIC, such as release of cancer cell antigens, immune cells recruiting and killing of cancer cells, was significantly higher in patients with high glycosylation score than those with low glycosylation score (Figure 4C; Supplementary Table S10). Furthermore, we examined the relationship between the glycosylation risk score and the enrichment score of gene features related to 21 immunotherapy-related pathways that summarized by Mariathasan et al. (2018). The findings revealed that the glycosylation score group exhibited higher pathway enrichment scores (Figure 4D). Finally, based on the TIS score of predicting immune checkpoint blocker (ICB) efficacy summarized by our team’s previous research, we observed that the patients with higher glycosylation score also had higher TIS scores (Figure 4E). The consistency of the above results indicated that the high glycosylation score group was more inclined to express the “hot-immune” TME, and was predicted to be more sensitive to immunotherapy.
FIGURE 4
Verifying the relationship between glycosylation score and TIME in a real-world BLCA cohort
Based on glycosylation scores to predict the expression of TME immunophenotype in TCGA-BLCA, we verified how glycosylation affects the TIME in real BLCA patients in Xiangya Hospital. Like previous research ideas, in 7-step CIC (Figure 5A, left; Supplementary Table S11), we found that patients with high glycosylation scores were more activated in the main anti-tumor immune steps, including. Correspondingly, the level of immune cell infiltration in the TIME was significantly increased in patients with high scores (Figure 5A, right; Supplementary Table S12), including. Furthermore, as shown in Figure 5B (Supplementary Table S13), patients with high glycosylation scores also expressed more ICI (up) and TIS (down) related genes, further confirming the activity of immune cells in their TME. As for immune cell effector genes, the results strongly suggested that patients with higher glycosylation score express more effector genes for CD8+T cells, DC, macrophages, NK cells, and Th1 cells (Figure 5C). Based on the multiple verifications of glycosylation and immunity in TCGA-BLCA and Xiangya-BLCA, we conclude that patients with higher glycosylation scores often exhibited a “hot” TIME, which mad their efficacy in immunotherapy more ideal.
FIGURE 5
Glycosylation score guided precision medicine in BLCA by predicting molecular subtypes
The gene expression profiling of MIBC has revealed that it was a heterogeneous disease, that can be sub-grouped into a variety of molecular subtypes, and shared significantly different prognoses and responses to anti-tumor treatments (Sjödahl et al., 2012; Comprehensive molecular characterization of urothelial, 2014; Fu et al., 2018; McConkey and Choi, 2018). The most common and recognized molecular typing standards were as follows, consensus subtype (Kamoun et al., 2020), TCGA subtype (Robertson et al., 2017), Cartes d’Identité des Tumeurs-Curie (CIT) subtype (Rebouissou et al., 2014), Lund subtype (Marzouka et al., 2018), Baylor subtype (Mo et al., 2018), University of North Carolina (UNC) subtype (Damrauer et al., 2014), MDAnderson Cancer Center (MDA) subtype (Choi et al., 2014). Our previous research integrated and simplified the above 7 typing standards to promote the clinical implementation of BLCA molecular subtypes (Li et al., 2021).
We found high consistency in the results between the public training cohort TCGA-BLCA (Figure 6A, up) and our real-world research cohort Xiangya-BLCA (Figure 6A, down). Among all the classification criteria, the basal subtype was more inclined to obtain higher glycosylation score, while the luminal subtype was more inclined to obtain lower glycosylation score. And, patients with high glycosylation score tend to exhibit basal differentiation characteristics, such as EMT differentiation, Immune differentiation, basal differentiation, interferon response, and so on. Simultaneously, patients in the with low glycosylation score were more inclined to exhibit luminal differentiation, like luminal differentiation and urothelial differentiation. As for the accuracy of glycosylation score in predicting BLCA molecular subtype, in TCGA-BLCA (Figure 6B), most AUCs exceed 0.73, and in Xiangya BLCA (Figure 6C), most AUCs even exceed 0.87.
FIGURE 6
Previous studies (Seiler et al., 2017; Kamoun et al., 2020) have shown that the differentiation of the Basal subtype BLCA is lower than that of the Luminal subtype, resulting in poorer prognosis. However, it has a higher response rate to immunotherapy such as cisplatin and ICB. Our study showed that BLCA patients with high glycosylation score had poor prognosis but more immune cell infiltration due to a tendency towards lower differentiated Basal subtype.
Discussion
Neoadjuvant chemotherapy based on cisplatin, followed by radical cystectomy and urinary tract diversion, remains the standardized treatment plan for locally advanced MIBC since the early 21st century (Author Anonymous, 1999; Grossman et al., 2003). Glycosylation is involved in many fundamental cellular events, including cell migration, cell signaling, growth and intercellular adhesion, cell signaling, and growth, and is one of the most common post translational modifications of proteins (Fuster and Esko, 2005). And, abnormal glycosylation is also considered an indispensable part of the carcinogenesis process (Ni et al., 2014), including BLCA. The research on protein modification and tumor heterogeneity, as well as the prediction of immunotherapy efficacy such as ICB, remains a hot topic in many cancers (Liu et al., 2021; Liu et al., 2022). Therefore, our research was dedicated to deeply exploring the association between glycosylation and BLCA, with the goal of accurately predicting prognosis and individualized guidance for treatment of BLCA.
Firstly, based on the expression feature of 628 glycosylation genes in each TCGA-BLCA patient, we obtained the most appropriate two clusters through consensus clustering, named glycosylation cluster 1 and glycosylation cluster 2. The results indicated that the patients in glycosylation cluster 2 had poor prognosis but more immune cell infiltration into the TME. The poor prognosis and unsatisfactory treatment response of cancer are mostly related to complex TME (Siegel et al., 2021), with the role of immune cells and related pathways being important factors. Therefore, we hoped to further develop the quantitative value of glycosylation genes in predicting prognosis and immunophenotype of BLCA. In addition, in recent years, research on the mechanism of glycosylation in BLCA had made progress (Wu et al., 2021; Tan et al., 2022), but research on the development of risk score to evaluate the prognosis of BLCA was still lacking. Therefore, we constructed a model by screening candidate genes that were strongly correlated with prognosis and most representative of glycosylation gene expression characteristics, and for the first time developed a glycosylation risk score that can comprehensively predict the prognosis, immune phenotype, and molecular subtype of BLCA.
Tumor cells had a faster rate of protein glycosylation than normal cells (Beatson et al., 2016), and a prospective multi-omics study on ovarian cancer by Hu et al. (2020). Further demonstrated that there was a significant differential expression of glycosylation between cancer cells and normal cells, and the degree of glycosylation difference could be reflected by the expression of glycoproteins in cancer cells. Some studies had shown that the abnormal mutation of the glycosylation related gene GALNT1 would lead to the occurrence and progression of a variety of cancers, including BLCA (Dyrskjøt et al., 2009). The activity of tumor infiltrating immune cells (TIICs), especially tumor infiltrating lymphocytes (TIL), in TME directly determines the survival outcome of tumor patients (Fridman et al., 2012), including early pT1 BLCA (Hülsen et al., 2020). In addition, the development of new targets, such as BCAT2, EMT-related signature and S100A5 (Xiao et al., 2022; Cai et al., 2023; Li et al., 2023), was playing an increasingly important role in immunotherapy for BLCA. A multicenter cohort study involving 709 patients (Bajorin et al., 2021) suggested that BLCA patients who still had a high risk of recurrence after surgery should be assisted with nivolumab. In this study, patients with high glycosylation scores had worse prognosis but presented a “hot” TIME (Duan et al., 2020) with high immune cell infiltration, and this result was highly consistent in the training set TCGA-BLCA and our own real-world cohort Xiangya-BLCA. Badmann S. et al.'s study (Badmann et al., 2020) provided a possible explanation for this phenomenon: in ovarian cancer, glycosylation could promote macrophage differentiation towards anti-inflammatory M2 type, leading to immune escape of cancer cells in immune activated TME.
Previous studies had shown that molecular typing can refine the prognosis and immune microenvironment of tumors. For example, in the study of breast cancer, it was found that the TILs infiltration level of different molecular subtypes of HR + breast cancer was quite different, in which TILs infiltration only prolongs OS, not disease-free survival (DFS) (Denkert et al.,2018). That was to say, different molecular subtypes exhibit different TIME (Goldberg et al., 2021). Rethinking the criteria for tumor molecular typing had become a hot topic, such as refining, updating, integrating, and simplifying. For example, the 5 mC regulator subtype system developed by our team in the previous study can accurately predict molecular typing in BLCA (Hu et al., 2021b). Moreover, the establishment of a consensus molecular subtype standard in gastric adenocarcinoma (GAC) to reclassify it and predict the response rate to ICB treatment (Wu et al., 2022), and a new standard developed by our team (Li et al., 2021) that integrate multiple mainstream molecular subtypes of BLCA will bring molecular typing closer to tumor treatment practice. In addition, Miao et al. (2022) reported that a glycosylation related protein B3GNT5 was specifically overexpressed in basal-like breast cancer (BLBR), revealing the close relationship between glycosylation and cancer molecular subtype. In this study, BLCA patients with high glycosylation score tended to differentiate into basal subtype, and they had “hot” TIME characteristics, but had poor prognosis. However, patients with low glycosylation score exhibited opposite luminal subtype, as well as corresponding prognosis and immune phenotype. In summary, patients with high glycosylation score would have better expected efficacy in receiving immunotherapy such as ICB, so more efforts should be made to explore new immunotherapies to improve the prognosis after treatment. On the contrary, patients with low glycation score should focus more on the development of targeted therapies and other therapies. This result also confirmed the previous research on the impact of molecular subtype on tumor prognosis and immunity phenotype (Choi et al., 2014; Hodgson et al., 2018).
Finally, there are some limitations that need to be further explored and supplemented in future research in this study. First, the materials of this study were retrospective data, and the influence between glycosylation and prognosis, immunophenotype and molecular typing of BLCA mostly stops at the level of correlation. Therefore, we plan to take this study as a pre-study and carry out prospective research on glycosylation and immunotherapy and targeted therapy of BLCA in the follow-up series of studies. In addition, based on this study and more literature review, combined with experimental conditions, we will conduct research on the mechanism of glycosylation related genes affecting BLCA treatment, committed to developing new therapeutic targets to promote precise treatment of BLCA.
Conclusion
Our study constructed a glycosylation score related to BLCA through multi-omics data, and predicted the tumor heterogeneity, prognosis and immunophenotype of BLCA. Glycosylation score can reliably predict the efficacy of immunotherapy and molecular subtypes of BLCA, which is conducive to individualized treatment decisions of BLCA patients.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
Ethics statement
The studies involving humans were approved by the Medical Ethics Committee of Xiangya Hospital Central South University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participant’s legal guardians/next of kin in accordance with the national legislation and institutional requirements.
Author contributions
JL: Conceptualization, Methodology, Resources, Writing–original draft, Writing–review and editing, Formal Analysis, Investigation, Software, Visualization. YH: Conceptualization, Methodology, Resources, Visualization, Writing–original draft. WZ: Conceptualization, Methodology, Resources, Visualization, Writing–original draft. ZT: Conceptualization, Methodology, Resources, Visualization, Writing–original draft. ZX: Conceptualization, Methodology, Resources, Writing–original draft, Funding acquisition, Project administration, Supervision, Validation, Writing–review and editing.
Funding
The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (81873626, 82070785, 82270816), Hunan Natural Science Foundation (2020JJ5884) and Hunan Province Young Talents Program (2021RC3027).
Acknowledgments
We sincerely thank all participants in the study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1280428/full#supplementary-material
Glossary
| BLCA | bladder cancer |
| NMIBC | non-muscle invasive bladder cancer |
| MIBC | muscle-invasive bladder cancer |
| TIME | tumor immune microenvironment |
| TME | tumor microenvironment |
| TCGA | the Cancer Genome Atlas |
| GDC | Genomic Data Commons |
| FPKM | fragments per kilobase of exon model per million mapped fragments |
| TPM | transcripts per kilobase of exon model per million mapped reads |
| GEO | Gene Expression Omnibus |
| RNA-seq | RNA-sequencing |
| GSEA | gene set enrichment analysis |
| TIP | tracking tumor immunophenotype |
| CIC | Cancer Immunity Cycle |
| ICI | immune checkpoint inhibitor |
| TIS | T cell-associated inflammatory signature |
| DCs | dendritic cells |
| NK | natural killer |
| Th1 | type 1 T helper |
| LASSO | least absolute shrinkage and selection operator |
| K-M | Kaplan-Meier |
| tROC | time-dependent receiver operating characteristic |
| HR | hazard ratio |
| ROC | receiver operating characteristic |
| AUC | area under the curve |
| ssGSEA | single sample gene set enrichment analysis |
| ICB | immune checkpoint blocker |
| TIICs | tumor infiltrating immune cells |
| TIL | tumor infiltrating lymphocytes |
| DFS | disease-free survival |
| GAC | gastric adenocarcinoma |
| BLBR | basal-like breast cancer |
References
1
AntoniS.FerlayJ.SoerjomataramI.ZnaorA.JemalA.BrayF. (2017). Bladder cancer incidence and mortality: A global overview and recent trends. Eur. Urol.71 (1), 96–108. 10.1016/j.eururo.2016.06.010
2
Author Anonymous (1999). Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International collaboration of trialists. Lancet354 (9178), 533–540. 10.1016/S0140-6736(99)02292-8
3
BadmannS.HeubleinS.MayrD.ReischerA.LiaoY.KolbenT.et al (2020). M2 macrophages infiltrating epithelial ovarian cancer express MDR1: A feature that may account for the poor prognosis. Cells9 (5), 1224. 10.3390/cells9051224
4
BajorinD. F.WitjesJ. A.GschwendJ. E.SchenkerM.ValderramaB. P.TomitaY.et al (2021). Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med.384 (22), 2102–2114. 10.1056/NEJMoa2034442
5
BeatsonR.Tajadura-OrtegaV.AchkovaD.PiccoG.TsourouktsoglouT.-D.KlausingS.et al (2016). The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat. Immunol.17 (11), 1273–1281. 10.1038/ni.3552
6
BinnewiesM.RobertsE. W.KerstenK.ChanV.FearonD. F.MeradM.et al (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med.24 (5), 541–550. 10.1038/s41591-018-0014-x
7
BonaventuraP.ShekarianT.AlcazerV.Valladeau-GuilemondJ.Valsesia-WittmannS.AmigorenaS.et al (2019). Cold tumors: A therapeutic challenge for immunotherapy. Front. Immunol.10, 168. 10.3389/fimmu.2019.00168
8
CaiZ.ChenJ.YuZ.LiH.LiuZ.DengD.et al (2023). BCAT2 shapes a noninflamed tumor microenvironment and induces resistance to anti-PD-1/PD-L1 immunotherapy by negatively regulating proinflammatory chemokines and anticancer immunity. Adv. Sci. (Weinheim, Baden-Wurttemberg, Ger.10 (8), e2207155. 10.1002/advs.202207155
9
ChenD. S.MellmanI. (2017). Elements of cancer immunity and the cancer-immune set point. Nature541 (7637), 321–330. 10.1038/nature21349
10
ChenD. S.MellmanI. (2013). Oncology meets immunology: The cancer-immunity cycle. Immunity39 (1), 1–10. 10.1016/j.immuni.2013.07.012
11
ChoiW.PortenS.KimS.WillisD.PlimackE. R.Hoffman-CensitsJ.et al (2014). Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell25 (2), 152–165. 10.1016/j.ccr.2014.01.009
12
ColapricoA.SilvaT. C.OlsenC.GarofanoL.CavaC.GaroliniD.et al (2016). TCGAbiolinks: an R/bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res.44 (8), e71. 10.1093/nar/gkv1507
13
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature507 (7492), (2014). 315–322. 10.1038/nature12965
14
DamrauerJ. S.HoadleyK. A.ChismD. D.FanC.TiganelliC. J.WobkerS. E.et al (2014). Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci. U. S. A.111 (8), 3110–3115. 10.1073/pnas.1318376111
15
DenkertC.von MinckwitzG.Darb-EsfahaniS.LedererB.HeppnerB. I.WeberK. E.et al (2018). Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet. Oncol.19 (1), 40–50. 10.1016/S1470-2045(17)30904-X
16
DuanQ.ZhangH.ZhengJ.ZhangL. (2020). Turning cold into hot: firing up the tumor microenvironment. Trends Cancer6 (7), 605–618. 10.1016/j.trecan.2020.02.022
17
DyrskjøtL.OstenfeldM. S.BramsenJ. B.SilahtarogluA. N.LamyP.RamanathanR.et al (2009). Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res.69 (11), 4851–4860. 10.1158/0008-5472.CAN-08-4043
18
EichlerJ. (2019). Protein glycosylation. Curr. Biol. CB29 (7), R229–R231. 10.1016/j.cub.2019.01.003
19
FridmanW. H.PagèsF.Sautès-FridmanC.GalonJ. (2012). The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer12 (4), 298–306. 10.1038/nrc3245
20
FuH.ZhuY.WangY.LiuZ.ZhangJ.XieH.et al (2018). Identification and validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer. Clin. Cancer Res. Official J. Am. Assoc. For Cancer Res.24 (13), 3069–3078. 10.1158/1078-0432.CCR-17-2687
21
FusterM. M.EskoJ. D. (2005). The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer5 (7), 526–542. 10.1038/nrc1649
22
GalonJ.BruniD. (2019). Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov.18 (3), 197–218. 10.1038/s41573-018-0007-y
23
GoldbergJ.PastorelloR. G.ValliusT.DavisJ.CuiY. X.AgudoJ.et al (2021). The immunology of hormone receptor positive breast cancer. Front. Immunol.12, 674192. 10.3389/fimmu.2021.674192
24
GrossmanH. B.NataleR. B.TangenC. M.SpeightsV. O.VogelzangN. J.TrumpD. L.et al (2003). Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med.349 (9), 859–866. 10.1056/NEJMoa022148
25
HodgsonA.LiuS. K.VespriniD.XuB.DownesM. R. (2018). Basal-subtype bladder tumours show a 'hot' immunophenotype. Histopathology73 (5), 748–757. 10.1111/his.13696
26
HuJ.ChenJ.OuZ.ChenH.LiuZ.ChenM.et al (2022). Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study. Cell Rep. Med.3 (11), 100785. 10.1016/j.xcrm.2022.100785
27
HuJ.OthmaneB.YuA.LiH.CaiZ.ChenX.et al (2021b). 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. BMC Med.19 (1), 289. 10.1186/s12916-021-02163-6
28
HuJ.YuA.OthmaneB.QiuD.LiH.LiC.et al (2021a). Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics11 (7), 3089–3108. 10.7150/thno.53649
29
HuY.PanJ.ShahP.AoM.ThomasS. N.LiuY.et al (2020). Integrated proteomic and glycoproteomic characterization of human high-grade serous ovarian carcinoma. Cell Rep.33 (3), 108276. 10.1016/j.celrep.2020.108276
30
HülsenS.LippolisE.FerrazziF.OttoW.DistelL.FietkauR.et al (2020). High stroma T-cell infiltration is associated with better survival in stage pT1 bladder cancer. Int. J. Mol. Sci.21 (21), 8407. 10.3390/ijms21218407
31
JenkinsR. W.BarbieD. A.FlahertyK. T. (2018). Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer118 (1), 9–16. 10.1038/bjc.2017.434
32
KamounA.de ReyniesA.AlloryY.SjodahlG.RobertsonA. G.SeilerR.et al (2020). A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol.77 (4), 420–433. 10.1016/j.eururo.2019.09.006
33
LenisA. T.LecP. M.ChamieK.MshsM. D. (2020). Bladder cancer: A review. JAMA324 (19), 1980–1991. 10.1001/jama.2020.17598
34
LiH.ChenJ.LiZ.ChenM.OuZ.MoM.et alS100A5 attenuates efficiency of anti-PD-L1/PD-1 immunotherapy by inhibiting CD8+ T cell-mediated anti-cancer immunity in bladder carcinoma. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 2023: p. e2300110.
35
LiH.LiuS.LiC.XiaoZ.HuJ.ZhaoC. (2021). TNF family-based signature predicts prognosis, tumor microenvironment, and molecular subtypes in bladder carcinoma. Front. Cell Dev. Biol.9, 800967. 10.3389/fcell.2021.800967
36
LiuX. S.LiuC.ZengJ.ZengD. B.ChenY. J.TanF.et al (2022). Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis. Front. Pharmacol.13, 1010879. 10.3389/fphar.2022.1010879
37
LiuX. S.LiuJ. M.ChenY. J.LiF. Y.WuR. M.TanF.et al (2021). Comprehensive analysis of hexokinase 2 immune infiltrates and m6A related genes in human esophageal carcinoma. Front. Cell Dev. Biol.9, 715883. 10.3389/fcell.2021.715883
38
MaW.GilliganB. M.YuanJ.LiT. (2016). Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J. Hematol. Oncol.9 (1), 47. 10.1186/s13045-016-0277-y
39
MariathasanS.TurleyS. J.NicklesD.CastiglioniA.YuenK.WangY.et al (2018). TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature554 (7693), 544–548. 10.1038/nature25501
40
MarzoukaN. A.ErikssonP.RoviraC.LiedbergF.SjodahlG.HoglundM. (2018). A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci. Rep.8 (1), 3737. 10.1038/s41598-018-22126-x
41
McConkeyD. J.ChoiW. (2018). Molecular subtypes of bladder cancer. Curr. Oncol. Rep.20 (10), 77. 10.1007/s11912-018-0727-5
42
MiaoZ.CaoQ.LiaoR.ChenX.LiX.BaiL.et al (2022). Elevated transcription and glycosylation of B3GNT5 promotes breast cancer aggressiveness. J. Exp. Clin. Cancer Res. CR41 (1), 169. 10.1186/s13046-022-02375-5
43
MoQ.NikolosF.ChenF.TramelZ.LeeY. C.HayashiK.et al (2018). Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J. Natl. Cancer Inst.110 (5), 448–459. 10.1093/jnci/djx243
44
MoremenK. W.TiemeyerM.NairnA. V. (2012). Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol.13 (7), 448–462. 10.1038/nrm3383
45
NiJ.JiangZ.ShenL.GaoL.YuM.XuX.et al (2014). β3GnT8 regulates the metastatic potential of colorectal carcinoma cells by altering the glycosylation of CD147. Oncol. Rep.31 (4), 1795–1801. 10.3892/or.2014.3042
46
PinhoS. S.ReisC. A. (2015). Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer15 (9), 540–555. 10.1038/nrc3982
47
PlimackE. R.BellmuntJ.GuptaS.BergerR.ChowL. Q. M.JucoJ.et al (2017). Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, open-label, phase 1b study. Lancet. Oncol.18 (2), 212–220. 10.1016/S1470-2045(17)30007-4
48
PowlesT.BellmuntJ.ComperatE.De SantisM.HuddartR.LoriotY.et al (2022). Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. Official J. Eur. Soc. For Med. Oncol.33 (3), 244–258. 10.1016/j.annonc.2021.11.012
49
PrzybyloM.Hoja-LukowiczD.LitynskaA.LaidlerP. (2002). Different glycosylation of cadherins from human bladder non-malignant and cancer cell lines. Cancer Cell Int.2, 6. 10.1186/1475-2867-2-6
50
RebouissouS.Bernard-PierrotI.de ReynièsA.LepageM. L.KruckerC.ChapeaublancE.et al (2014). EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl. Med.6 (244), 244ra91. 10.1126/scitranslmed.3008970
51
RijndersM.de WitR.BoormansJ. L.LolkemaM. P. J.van der VeldtA. A. M. (2017). Systematic review of immune checkpoint inhibition in urological cancers. Eur. Urol.72 (3), 411–423. 10.1016/j.eururo.2017.06.012
52
RobertsonA. G.KimJ.Al-AhmadieH.BellmuntJ.GuoG.CherniackA. D.et al (2017). Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell171 (3), 540–556.e25. 10.1016/j.cell.2017.09.007
53
RodrÍguezE.SchettersS. T. T.van KooykY. (2018). The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat. Rev. Immunol.18 (3), 204–211. 10.1038/nri.2018.3
54
RosenbergJ. E.Hoffman-CensitsJ.PowlesT.van der HeijdenM. S.BalarA. V.NecchiA.et al (2016). Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet (London, Engl.387 (10031), 1909–1920. 10.1016/S0140-6736(16)00561-4
55
SchoenfeldA. J.HellmannM. D. (2020). Acquired resistance to immune checkpoint inhibitors. Cancer Cell37 (4), 443–455. 10.1016/j.ccell.2020.03.017
56
SeilerR.AshabH. A. D.ErhoN.van RhijnB. W. G.WintersB.DouglasJ.et al (2017). Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol.72 (4), 544–554. 10.1016/j.eururo.2017.03.030
57
SiegelR. L.MillerK. D.FuchsH. E.JemalA. (2021). Cancer statistics, 2021. CA a Cancer J. For Clin.71 (1), 7–33. 10.3322/caac.21654
58
SiegelR. L.MillerK. D.JemalA.FedewaS. A.ButterlyL. F.AndersonJ. C.et al (2020). Colorectal cancer statistics, 2020. CA a Cancer J. For Clin.70 (1), 145–164. 10.3322/caac.21601
59
SjödahlG.LaussM.LövgrenK.ChebilG.GudjonssonS.VeerlaS.et al (2012). A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. Official J. Am. Assoc. For Cancer Res.18 (12), 3377–3386. 10.1158/1078-0432.CCR-12-0077-T
60
SunR.KimA. M. J.LimS.-O. (2021). Glycosylation of immune receptors in cancer. Cells10 (5), 1100. 10.3390/cells10051100
61
TanZ.JiangY.LiangL.WuJ.CaoL.ZhouX.et al (2022). Dysregulation and prometastatic function of glycosyltransferase C1GALT1 modulated by cHP1BP3/miR-1-3p axis in bladder cancer. J. Exp. Clin. Cancer Res. CR41 (1), 228. 10.1186/s13046-022-02438-7
62
VarkiA. (2017). Biological roles of glycans. Glycobiology27 (1), 3–49. 10.1093/glycob/cww086
63
VonderheideR. H. (2020). CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med.71, 47–58. 10.1146/annurev-med-062518-045435
64
WilkersonM. D.HayesD. N. (2010). ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics26 (12), 1572–1573. 10.1093/bioinformatics/btq170
65
WuJ.TanZ.LiH.LinM.JiangY.LiangL.et al (2021). Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing O-GlcNAcylation of cyclin-dependent-like kinase 5. J. Pineal Res.71 (3), e12765. 10.1111/jpi.12765
66
WuX.YeY.VegaK. J.YaoJ. (2022). Consensus molecular subtypes efficiently classify gastric adenocarcinomas and predict the response to anti-PD-1 immunotherapy. Cancers14 (15), 3740. 10.3390/cancers14153740
67
XiaoZ.CaiZ.DengD.TongS.ZuX. (2022). An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer. Front. Immunol.13, 1000321. 10.3389/fimmu.2022.1000321
68
XuL.DengC.PangB.ZhangX.LiuW.LiaoG.et al (2018). Tip: A web server for resolving tumor immunophenotype profiling. Cancer Res.78 (23), 6575–6580. 10.1158/0008-5472.CAN-18-0689
Summary
Keywords
glycosylation, multi-omics, tumor heterogeneity, immunotherapeutic efficacy, molecular subtype, bladder carcinoma
Citation
Liu J, He Y, Zhou W, Tang Z and Xiao Z (2023) A glycosylation risk score comprehensively assists the treatment of bladder neoplasm in the real-world cohort, including the tumor microenvironment, molecular and clinical prognosis. Front. Pharmacol. 14:1280428. doi: 10.3389/fphar.2023.1280428
Received
20 August 2023
Accepted
11 September 2023
Published
25 September 2023
Volume
14 - 2023
Edited by
Hongzhou Cai, Nanjing Medical University, China
Reviewed by
Wanzun Lin, Fudan University, China
Fahui Liu, Xiamen University, China
Xu-Sheng Liu, Hubei University of Medicine, China
Updates
Copyright
© 2023 Liu, He, Zhou, Tang and Xiao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zicheng Xiao, xzcheng1998@163.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.